| Literature DB >> 28572668 |
Haining Yu1, Chen Wang2, Lan Feng2, Shasha Cai2, Xuelian Liu2, Xue Qiao2, Nannan Shi2, Hui Wang2, Yipeng Wang3.
Abstract
Cathelicidins are regarded as promising antibiotics due to their capability against antibiotic-resistant bacteria without cytotoxicity. However, some concerns about the balance of cytotoxicity and antimicrobial activity, weak stability and enzymatic susceptibility sually restrict their therapeutic use. Here, we designed a series of shortened variants, Hc1~15, based on our previously characterized Hc-CATH. Hc3, the one with the best activity, after point mutation was engineered with a trypsin inhibitor loop, ORB-C, to obtain four hybrid peptides: H3TI, TIH3, H3TIF and TIH3F. All four except TIH3 were found possessing an appreciable profile of proteases inhibitory and antimicrobial characteristics without increase in cytotoxicity. Among them, TIH3F exhibited the most potent and broad-spectrum antimicrobial and anti-inflammatory activities. Fluorescence spectroscopy has demonstrated a quick induction of bacterial membrane permeability by TIH3F leading to the cell death, which also accounts for its fast anti-biofilm activity. Such mode of antimicrobial action was mainly attributed to peptides' amphiphilic and helical structures determined by CD and homology modeling. Besides, TIH3F exhibited good tolerance to salt, serum, pH, and temperature, indicating a much better physiological stability in vitro than Hc3, Most importantly, in the case of resistance against proteases hydrolysis, current hybrid peptides displayed a remarkable enhancement than their original templates.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28572668 PMCID: PMC5453931 DOI: 10.1038/s41598-017-02050-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Antimicrobial activities of Hc-CATH and its truncated derivatives.
| Peptide | Sequence | MIC (µg/mL) | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
| Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | 2.34 | 0.59 | 4.69 | 18.75 | 4.69 | 75 | 4.69 |
| Hc1 | KFFKRLLKSVRRAVKKFRK [NH2] | 18.75 | 4.69 | 9.38 | 9.38 | 4.69 | 18.75 | 9.38 |
| Hc2 | KFFKRLLKSVRRAVKKFR [NH2] | 9.38 | 2.34 | 9.38 | 9.38 | 9.38 | 18.75 | 9.38 |
| Hc3 | KFFKRLLKSVRRAVKKF [NH2] | 18.75 | 2.34 | 4.68 | 9.38 | 9.38 | 9.38 | 9.38 |
| Hc4 | KFFKRLLKSVRRAVKK [NH2] | 75 | 4.69 | 75 | 150 | 75 | — | 75 |
| Hc5 | KFFKRLLKSVRRAVK [NH2] | 37.5 | 4.69 | 18.75 | 75 | 37.5 | 150 | 37.5 |
| Hc6 | KFFKRLLKSVRRAV [NH2] | 75 | 18.75 | 37.5 | 150 | 75 | 150 | 75 |
| Hc7 | KFFKRLLKSVRRA [NH2] | — | 75 | — | 150 | — | — | — |
| Hc8 | FFKRLLKSVRRAVKKFRK [NH2] | 18.75 | 4.69 | 18.75 | 18.75 | — | 37.5 | 9.38 |
| Hc9 | FKRLLKSVRRAVKKFRK [NH2] | 150 | 18.75 | — | 150 | 9.38 | — | 150 |
| Hc10 | KRLLKSVRRAVKKFRK [NH2] | — | — | — | — | — | — | — |
| Hc11 | RLLKSVRRAVKKFRK [NH2] | — | 150 | — | — | — | — | — |
| Hc12 | LLKSVRRAVKKFRK [NH2] | — | — | — | — | — | — | — |
| Hc13 | LKSVRRAVKKFRK [NH2] | — | — | — | — | — | — | — |
| Hc14 | FFKRLLKSVRRAVKKF [NH2] | 18.75 | 4.69 | 9.38 | 37.5 | 9.38 | 37.5 | 150 |
| Hc15 | FKRLLKSVRRAVKKF [NH2] | 75 | 37.5 | — | — | — | — | — |
MIC: minimal inhibitory concentration. These concentrations represent the mean values of three independent experiments performed in duplicate. —, no detectable activity in the inhibition zone assay at peptide dose of 2 mg/mL.
Hemolysis rates of the peptides.
| Conc. (μg/mL) | 12.5 | 25 | 50 | 100 | 200 |
|---|---|---|---|---|---|
| Hc-CATH | — | — | — | — | 5.25 |
| Hc1 | 1.09 | 2.90 | 3.26 | 4.35 | 8.33 |
| Hc2 | 1.45 | 0.36 | 1.09 | 2.90 | 3.98 |
| Hc3 | 2.17 | 4.35 | 5.43 | 5.80 | 6.88 |
| Hc4 | 2.90 | 1.81 | 1.09 | 2.54 | 4.71 |
| Hc5 | 3.62 | 1.09 | 2.90 | 5.43 | 5.07 |
| Hc6 | 1.45 | 2.90 | 1.81 | 0.72 | 3.62 |
| Hc7 | 2.17 | 1.45 | 0.72 | 3.26 | 5.07 |
| Hc8 | 2.17 | 3.62 | 0.36 | 2.17 | 1.45 |
| Hc9 | 3.99 | 2.90 | 2.54 | 2.54 | 4.17 |
| Hc10 | 2.17 | 2.90 | 3.99 | 1.81 | 2.17 |
| Hc11 | 4.71 | 3.26 | 2.90 | 4.71 | 5.80 |
| Hc12 | 2.17 | 1.45 | 0.11 | 4.35 | 3.99 |
| Hc13 | 1.45 | 1.81 | 0.36 | 1.45 | 4.16 |
| Hc14 | 3.98 | 2.54 | 1.98 | 1.36 | 3.26 |
| Hc15 | 3.62 | 4.35 | 5.07 | 8.70 | 9.06 |
| H3TI | 1.80 | 1.55 | 2.28 | 3.50 | 7.39 |
| H3TIF | 1.60 | 1.23 | 1.96 | 2.35 | 5.53 |
| TIH3 | 1.94 | 0.94 | 1.76 | 3.17 | 3.08 |
| TIH3F | 4.91 | 2.62 | 5.44 | 6.41 | 10 |
Hemolysis rate of Hc-CATH, its truncated derivatives and four current hybrid peptides, “—” represents no assay.
Sequences and physicochemical parameters of the four hybrid peptides.
| Hybrid peptide | Amino acid sequence (Length) | Mw/pI | Net charge |
|---|---|---|---|
| H3TI | KFFKRLLKSVRRAVKKF | 3393.25Da/11.21 | 10 |
| H3TIF | KFFKR | 3557.37Da/11.21 | 10 |
| TIH3 |
| 3393.25Da/11.21 | 10 |
| TIH3F |
| 3557.37Da/11.21 | 10 |
The disulfidebridged hendecapeptide (CWTKSIPPKPC) proteinase inhibitor loop is indicated in italics and bold; the Phe mutations are underlined.
Figure1(A) Circular dichroism analyses of four hybrid peptides in 50% TFE solvent. (B) Helix-wheel plots and (C) tertiary structures built by homology model of four peptides. For helix-wheel plots, the hydrophobic and hydrophilic residues are separated with dash dot line, with the hydrophilic residues being concentrated on upper side of the helix and hydrophobic ones on the lower. For tertiary structures, the α-helix are displayed in the ribbon structure. Residues of Arg and Lys are displayed in blue and red, respectively in surface representatios.
Antimicrobial and trypsin-inhibitory activities of the four hybrid peptides.
| Microorganisms | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|
| H3TI | H3TIF | TIH3 | TIH3F | Hc3 | Ampicillin | |
|
| ||||||
|
| 37.5 | 37.5 | — | 9.38 | 18.75 | 4.69 |
|
| 9.38 | 4.69 | 150 | 4.69 | 37.5 | 9.38 |
|
| — | — | — | 75 | — | — |
|
| 37.5 | 37.5 | — | 9.38 | 9.38 | — |
|
| — | — | — | 75 | — | — |
|
| 9.38 | 4.69 | — | 4.69 | 2.34 | 75 |
|
| — | — | — | 75 | 75 | — |
|
| — | — | — | 75 | 75 | — |
|
| 37.5 | — | 75 | 9.38 | 4.68 | 75 |
|
| 18.75 | 4.69 | 150 | 9.38 | 9.38 | — |
|
| 37.5 | — | — | 9.38 | 9.38 | 9.38 |
|
| ||||||
|
| — | — | — | 75 | 75 | 18.75 |
|
| — | — | — | 75 | 75 | — |
|
| 37.5 | — | 37.5 | 2.37 | 9.38 | 9.38 |
|
| 9.38 | 37.5 | — | 4.69 | 9.38 | 75 |
|
| 9.38 | 9.38 | — | 4.69 | 9.38 | — |
|
| 18.75 | 4.69 | 18.75 | 2.37 | 4.69 | — |
|
| — | — | — | 37.5 | — | — |
|
| ||||||
|
| 4.69 | 4.69 | — | 4.69 | 9.38 | 18.75 |
|
| 4.69 | 9.38 | — | 4.69 | — | 18.75 |
|
| — | — | 37.5 | — | — | |
|
| ||||||
|
| 37.5 | 18.75 | 75 | 9.38 | 18.75 | 37.5 |
|
| 4.69 | 2.37 | 37.5 | 4.69 | 4.69 | 18.75 |
|
| 18.75 | 4.69 | — | 4.69 | — | — |
|
| 75 | 9.38 | — | 75 | — | — |
|
| — | 18.75 | — | 18.75 | — | — |
|
| — | 9.38 | — | 75 | 9.38 | — |
|
| 37.5 | — | 75 | 37.5 | — | — |
|
| 5.5 μM | 6.5 μM | 7.5 μM | 1.5 μM | ||
MIC: minimal inhibitory concentration. These concentrations represent mean values of three independent experiments performed in duplicates. —: no detectable activity in MIC assay in dose of 200 µg/mL or in trypsin inhibition assay at concentration of 160 μg/mL.
Bacterial killing kinetics of four hybrid peptides.
| Time | CFU × 103 ( | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 min | 10 min | 30 min | 1 h | 1.5 h | 2 h | 3 h | 6 h | |
| H3TI × 1 | 63 ± 13.4 | 45 ± 12.7 | 19 ± 7.6 | 17 ± 3.0 | 15 ± 1.6 | 14 ± 3.6 | 0 ± 0.0 | 0 ± 0.0 |
| H3TI × 5 | 58 ± 15.6 | 26 ± 6.4 | 5 ± 2.4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| H3TIF × 1 | 68 ± 14.9 | 47 ± 8.6 | 37 ± 9.3 | 21 ± 7.2 | 23 ± 8.5 | 16 ± 5.9 | 8 ± 3.1 | 0 ± 0.0 |
| H3TIF × 5 | 62 ± 13.7 | 9 ± 3.5 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3 × 1 | 60 ± 13.6 | 54 ± 20.7 | 45 ± 12.3 | 27 ± 6.9 | 19 ± 2.8 | 15 ± 3.5 | 5 ± 1.6 | 0 ± 0.0 |
| TIH3 × 5 | 57 ± 12.3 | 32 ± 11.3 | 12 ± 5.8 | 2 ± 0.6 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 1 | 65 ± 14.9 | 49 ± 12.7 | 24 ± 6.5 | 17 ± 4.5 | 12 ± 4.8 | 5 ± 2.1 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 5 | 61 ± 13.8 | 16 ± 6.7 | 3 ± 1.0 | 1 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Ampicillin × 1 | 70 ± 16.3 | 63 ± 18.4 | 57 ± 9.4 | 47 ± 8.6 | 37 ± 5.5 | 29 ± 3.7 | 24 ± 1.5 | 0 ± 0.0 |
| Ampicillin × 5 | 64 ± 15.4 | 46 ± 19.3 | 54 ± 3.5 | 24 ± 3.6 | 11 ± 4.7 | 3 ± 1.0 | 1 ± 1.0 | 0 ± 0.0 |
| Water | 56 ± 14.6 | 78 ± 16.8 | 131 ± 23.6 | 178 ± 17.9 | 286 ± 35.7 | 469 ± 56.8 | 1358 ± 172.6 | 18345 ± 345.3 |
|
| ||||||||
| H3TI × 1 | 60 ± 15.6 | 55 ± 7.4 | 45 ± 9.8 | 32 ± 6.0 | 23 ± 5.3 | 15 ± 4.3 | 0 ± 0.0 | 0 ± 0.0 |
| H3TI × 5 | 59 ± 8.3 | 21 ± 5.2 | 1 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3 × 1 | 64 ± 17.1 | 69 ± 15.2 | 54 ± 9.8 | 36 ± 8.8 | 32 ± 6.1 | 22 ± 3.5 | 8 ± 2.0 | 0 ± 0.0 |
| TIH3 × 5 | 59 ± 14.2 | 36 ± 13.5 | 8 ± 2.6 | 5 ± 1.7 | 1 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 1 | 69 ± 13.2 | 57 ± 6.2 | 30 ± 6.4 | 21 ± 5.7 | 11 ± 2.8 | 3 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 5 | 63 ± 7.5 | 16 ± 7.7 | 1 ± 0.6 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Ampicillin × 1 | 62 ± 17.6 | 66 ± 15.4 | 63 ± 15.8 | 58 ± 14.8 | 48 ± 8.2 | 31 ± 3.4 | 23 ± 2.6 | 5 ± 1.0 |
| Ampicillin × 5 | 58 ± 13.6 | 52 ± 16.2 | 43 ± 9.3 | 39 ± 14.5 | 13 ± 3.8 | 2 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 |
| Water | 66 ± 15.4 | 82 ± 26.4 | 130 ± 44.2 | 244 ± 38.3 | 329 ± 29.0 | 608 ± 82.3 | 1937 ± 242.8 | 21863 ± 683.5 |
|
| ||||||||
| H3TI × 1 | 65 ± 10.5 | 49 ± 6.6 | 45 ± 7.5 | 32 ± 6.0 | 23 ± 4.8 | 12 ± 2.6 | 0 ± 0.0 | 0 ± 0.0 |
| H3TI × 5 | 60 ± 9.5 | 15 ± 5.8 | 2 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| H3TIF × 1 | 66 ± 15.6 | 59 ± 7.5 | 47 ± 8.5 | 36 ± 7.5 | 19 ± 3.6 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| H3TIF × 5 | 62 ± 14.6 | 8 ± 1.3 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3 × 1 | 63 ± 16.3 | 47 ± 14.9 | 38 ± 7.5 | 25 ± 3.6 | 22 ± 6.6 | 5 ± 2.0 | 2 ± 0.8 | 0 ± 0.0 |
| TIH3 × 5 | 58 ± 13.7 | 32 ± 15.4 | 7 ± 2.3 | 3 ± 1.7 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 1 | 63 ± 7.9 | 44 ± 8.5 | 36 ± 5.5 | 21 ± 3.2 | 13 ± 1.7 | 2 ± 1.0 | 0 ± 0.0 | 0 ± 0.0 |
| TIH3F × 5 | 61 ± 8.3 | 19 ± 7.9 | 1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Meropenem × 1 | 62 ± 17.8 | 66 ± 18.5 | 57 ± 17.6 | 46 ± 15.2 | 44 ± 3.6 | 37 ± 4.5 | 33 ± 5.2 | 2 ± 1.0 |
| Meropenem × 5 | 57 ± 14.1 | 42 ± 17.9 | 31 ± 12.5 | 22 ± 11.4 | 15 ± 3.8 | 2 ± 1.4 | 0 ± 0.0 | 0 ± 0.0 |
| Water | 62 ± 18.2 | 84 ± 25.9 | 128 ± 42.1 | 254 ± 37.9 | 335 ± 28.4 | 612 ± 72.6 | 1756 ± 235.4 | 21786 ± 674.9 |
CFU: colony forming unit; 1xMIC and 5xMIC of samples were used in this experiment; The MICs of H3TI, H3TIF, TIH3, TIH3F and ampicillin against E. coli 08040726 are 9.38, 4.69, 150, 4.69 and 0.12 µg/mL, respectively; H3TI, H3TIF, TIH3, TIH3F and meropenem MICs to V. parahaemolyticus are 4.69, 2.37, 37.5, 9.38 and 0.47 µg/mL, respectively.
Figure 2Activities of TIH3, H3TI, H3TIF and TIH3F inhibiting C. albicans biofilms formation and killing C. albicans in established biofilms. (A) The inhibitory effect of TIH3, H3TI, H3TIF and TIH3F against C. albicans biofilm formation. C. albicans was grown in a 6-well plate with coverslip at 35 °C for 36 h in the presence of different concentrations of four peptides. Growth in control is set to 100% and percent of biofilm formed is indicated in different bar. Data are presented as the mean ± SD from three independent experiments (*P < 0.05; **P < 0.01; ***P < 0.001; by unpaired t test). (B) The killing effect of four hybrid peptides against C. albicans in the biofilms. Cells treated with peptides and amphotericin B of series concentrations, with negative control set to a 100%. Data are presented as the mean ± SD from three independent experiments. (C) Visualization of TIH3F killing C. albicans in established biofilms photographed by fluorescence microscope. Living cells stained by SYBR Green I are green and dead cells stained by PI are red.
Figure 3(A) Effects of various concentrations of NaCl on the antibacterial activity of Hc-3 and TIH3F against E. coli. (B) Stability of Hc-3 and TIH3F in human serum (20%). (C) Effects of pH value on the antibacterial activity Hc-3 and TIH3F against E. coli. (D) Thermal stability of Hc-3 and TIH3F at normal human body temperature of 37 °C. (E) Antimicrobial activities of Hc-3 and TIH3F under the influence of proteases (trypsin and proteinase K) against E. coli, S. aureus and C. albicans. (F) The degradation rates of Hc-3 and TIH3F after incubation with proteases (trypsin and proteinase K). Three separate experiments were performed to calculate the mean ± SD (*P < 0.05; **P < 0.01; by unpaired t test).
Figure 4Analytical reversed-phase HPLC traces of Hc-3 and TIH3F after treatment with trypsin for different times. (A) LC analysis of pure Hc-3. LC analysis of Hc-3 after incubation with trypsin at 37 °C for (B) 6 h (C) 12 h and (D) 24 h. (E) LC analysis of pure TIH3F. LC analysis of TIH3F after incubation with trypsin at 37 °C for (F) 6 h (G)12 h and (H) 24 h.
Figure 5Membrane permeabilization of hybrid peptide on E. coli (A), S. aureus (B) and C. albicans (C). The microorganisms were treated with presence (+) or absence (−) of TIH3F and PI staining.
Figure 6Effects of four hybrid peptides on the inflammatory factors: (A) iNOS & nitrite; (B) TNF-α; (C) IL-1β; (D) IL-6; (E) MCP-1 transcription and production induced by LPS. Expression of the target genes were measured by q-PCR and normalized against the expression of GAPDH. Target genes expression in untreated cells was normalized to 1. The secretions of NO, cytokines and chemokine in RAW 264.7 culture supernatant were determined by Griess reagent and ELISA, respectively. LPS: 100 ng/mL. Data are mean ± SEM value of three independent experiments (*P < 0.05; **P < 0.01; by unpaired t test).